



Date: 3rd July, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned matter, we are pleased to inform you that Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals Limited ("Company") has acquired Utility Therapeutics Ltd.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid acquisition is enclosed as Annexure – I.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl: A/a

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Annexure-I

Details as required under Regulation 30 of SEBI Listing Regulations read with Circular no SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024:

Sr. No.	Particulars	Details
i)	Name of the target entity, details in brief such as size, turnover etc.;	Utility Therapeutics Ltd. ("Utility")
ii)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Not Applicable. The proposed acquisition of Utility (by wholly owned subsidiary i.e. Alembic Pharmaceuticals Inc.) does not fall under related party transaction. The promoter / promoter/ promoter group are not interested in the transaction.
iii)	Industry to which the entity being acquired belongs;	Pharmaceuticals
iv)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To market the USFDA approved product and under-development product owned by the Utility in USA.
v)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
vi)	Indicative time period for completion of the acquisition;	Approx. 30 days.
vii)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration plus profit share out of future profits.
viii)	Cost of acquisition and/or the price at which the shares are acquired;	Approx \$12mn in staggered manner over period of time, depending on milestones achieved.
ix)	Percentage of shareholding / control acquired and / or number of shares acquired;	100%

ALEMBIC PHARMACEUTICALS LIMITED

x)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI).</p> <p>-“Pivya” is an FDA approved product to treat uncomplicated UTIs in the US market.</p> <p>-“MEC” is a product in development for the treatment of complicated UTIs in the US market.</p> <p>As a product development company they have minimal turnover in last 3 years.</p>
----	---	--

ALEMBIC PHARMACEUTICALS LIMITED